BioSpace News Archive

Illumina today announced that it will issue results for fourth quarter and fiscal year 2018 following the close of market on Tuesday, January 29, 2019.

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today a corporate restructuring to focus resources on its development pipeline, comprising five clinical-stage cancer programs in various solid tumor types and addressing multiple cell types in the tumor microenvironment.

With a new sensor designed from the ground-up, Hamamatsu Photonics have taken the strengths of EMCCD and sCMOS sensors to engineer the most advanced sCMOS camera available today; we proudly introduce the new ORCA-Fusion scientific CMOS Camera.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, announced today that it has dosed the first patient in a Phase 1/2 clinical trial of MRTX849, an investigational KRAS G12C inhibitor for patients with advanced solid tumors that harbor KRAS G12C mutations.

AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that the RECON® Study supporting its Biologic License Application (BLA) Submission for Avance® Nerve Graft has reached its current enrollment milestone of 170 subjects.

Today, Executive Insight celebrates the culmination of our partnership with One Family Health in Rwanda. For two years, Executive Insight has been supporting One Family Health (OFH) in its mission to make primary care more accessible to underserved communities.

Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) is pleased to announce that the Company has elected to exercise its right under the warrant indenture (the “Indenture”) governing the common share purchase warrants of the Company issued October 30, 2017 and originally scheduled to expire on October 30, 2019

A study examining the effect of a video educational intervention aimed at increasing HPV vaccinations among adolescents could help the Centers for Disease Control and Prevention meet its goal of getting more eligible adolescents vaccinated against certain cancers and diseases caused by the human papillomavirus (HPV).

These new antibodies and thousands of other monoclonal/polyclonal antibodies and conjugates are validated for use in a variety of common applications such as WB, FC, IHC, ICC, IF, IP, and more.

Getting access to high-quality health care can often be a challenge for many patients, but it’s not always impossible.